Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV1.7 sodium channels
British Journal of Pharmacology2014Vol. 171(19), pp. 4455–4463
Citations Over TimeTop 10% of 2014 papers
Abstract
Mexiletine has a normalizing effect on the pathological gating properties of the L858F gain-of-function mutation in NaV 1.7, which, in part, might explain the beneficial effects of systemic treatment with mexiletine in patients with gain-of-function sodium channel disorders.
Related Papers
- → Mexiletine-responsive erythromelalgia due to a new Nav1.7 mutation showing use-dependent current fall-off(2009)91 cited
- → Comparatibe actions of mexiletine on sodium channels in nerve, skeletal and cardiac muscle(1981)49 cited
- → Primary Erythromelalgia in a 12-Year-Old Boy: Positive Response to Sodium Channel Blockers Despite Negative SCN9A Mutations(2011)10 cited
- → Refractory erythromelalgia of the ears: response to mexiletine(2010)7 cited
- → Mexiletine-responsive Erythromelalgia Due To A New NaV1.7 Mutation Showing Use-dependent Block(2009)